# US 2024/0197785 A1 · Processing of tumor infiltrating lymphocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197785 A1
- Document ID: US20240197785A1
- Status: Published application
- Kind: A1
- Application number: 18/573,111
- Filed: 2022-06-22
- Published: 2024-06-20
- Earliest claimed: 2021-06-24
- Assignees: Instil Bio, Inc.
- Applicants: Instil Bio, Inc.
- Inventors: Sifat Ahmed; Kenny Choi; Holly Bethany Crookes; Robson Dossa; Jeremy Garibay; James Huston Glenn, IV; Paulina Nowosiad; Fitore Vlashi; Maize Wang
- Web page: https://patentgrep.com/patent/US20240197785A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- C12N 5/0635: {B lymphocytes}
- C12N 5/0636: {T lymphocytes}
- A01N 1/162: Temperature processes, e.g. following predefined temperature changes over time
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2502/11: blood or immune system cells
- C12N 2509/10: Mechanical dissociation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.

## Claims

### Claim 1

A method for preparing a therapeutic population of tumor infiltrating lymphocytes (TILs), comprising:
(a) obtaining a processed resected tumor product comprising TILs;
(b) performing a first expansion by culturing the processed resected tumor product in a first cell culture medium comprising IL-2 to produce a first population of TILs;
(c) performing a second expansion by culturing the first population of TILs in a second culture medium with IL-2, a CD3 agonist or a CD3 agonist antibody, and antigen presenting cells (APCs), to produce a second population of TILs; and
(d) harvesting the TILs.

### Claim 2 (depends on 1)

The method of claim 1, wherein step (a) comprises:
(i) cryopreserving a resected tumor and disaggregating the cryopreserved tumor;
(ii) disaggregating a resected tumor and cryopreserving the disaggregated tumor;
(iii) cryopreserving a resected tumor and processing the tumor into multiple tumor fragments; or
(iv) processing a resected tumor into multiple tumor fragments and cryopreserving the tumor fragments.

### Claim 3 (depends on 2)

The method of claim 2, further comprising a step of thawing and washing the processed resected tumor product prior to step (b).

### Claim 4 (depends on 3)

The method of claim 3, wherein the thawing and washing comprises removing a cryopreservant.

### Claim 5 (depends on 3, 4)

The method of claim 3 or 4, wherein the thawing and washing does not comprise a recovery period.

### Claim 6 (depends on 3, 4)

The method of claim 3 or 4, wherein the thawing and washing comprises a recovery period of from about 2 to about 4 hours, from about 4 to about 6 hours, from about 6 to about 9 hours, from about 9 to about 12 hours, from about 12 to about 18 hours, or from about 18 to about 24 hours.

### Claim 7 (depends on 1)

The method of claim 1, wherein the processed resected tumor product is a fresh processed resected tumor product that has not been cryopreserved.

### Claim 8

The method of any preceding claim, wherein step (a) comprises aseptically disaggregating a tumor resected from a subject to prepare the processed resected tumor product, wherein the disaggregation comprise repeated physical pressure applied 120 to 360 times per minute at up to 6 N/cm2 in the presence of an enzyme solution, wherein the tumor is disaggregated into a cell suspension so that the processed resected tumor product can be subjected to a cell culture process.

### Claim 9 (depends on 8)

The method of claim 8, wherein the resected tumor is not fragmented prior to disaggregation.

### Claim 10 (depends on 8, 9)

The method of claim 8 or 9, wherein the enzyme solution comprises DNase and collagenase.

### Claim 11 (depends on 8, 9, 10)

The method of any one of claims 8-10, wherein the disaggregation period is 90 minutes or less.

### Claim 12 (depends on 8, 9, 10, 11)

The method of any one of claims 8-11, wherein the processed resected tumor product is filtered prior to the first expansion.

### Claim 13 (depends on 12)

The method of claim 12, wherein the filtered processed resected tumor product constituents have an average size of less than 200 μm or less than 170 μm.

### Claim 14

The method of any preceding claim, wherein the processed resected tumor product is transduced to express a costimulatory receptor.

### Claim 15

The method of any preceding claim, wherein the TILs comprise UTILs or MTILs.

### Claim 16

The method of any preceding claim, wherein the tumor is from a melanoma, a cervical cancer, a non-small cell lung cancer (NSCLC), a head and neck squamous cell carcinoma (HNSCC), or a cutaneous squamous cell carcinoma (cSCC).

### Claim 17

The method of any preceding claim, wherein the first cell culture medium comprises between about 300 and about 3000 IU/mL IL-2.

### Claim 18

The method of any preceding claim, wherein the first cell culture medium comprises between about 1500 and about 2500 IU/mL IL-2 or between about 1750 and about 2250 IU/mL IL-2, or wherein the first cell culture medium comprises less than 3000, less than 2500, or less than 2250 IU/mL IL-2.

### Claim 19

The method of any preceding claim, wherein the first cell culture medium comprises about 2000 IU/mL of IL-2.

### Claim 20

The method of any preceding claim, wherein the first cell culture medium comprises fetal bovine serum (FBS).

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the first cell culture medium does not comprise fetal bovine serum (FBS).

### Claim 22

The method of any preceding claim, wherein the first cell culture medium comprises human AB serum.

### Claim 23

The method of any preceding claim, wherein the first cell culture medium further comprises IL-7, IL-12, IL-15, IL-18, IL-21, or a combination thereof.

### Claim 24

The method of any preceding claim, wherein step (b) comprises initially seeding the processed resected tumor product in a 70-mL cell culture bag.

### Claim 25

The method of any preceding claim, wherein step (b) comprises initially seeding the processed resected tumor product in about 20 to about 40 mL of the cell culture medium.

### Claim 26

The method of any preceding claim, wherein step (b) is from about 10 to about 13 days or from about 11 to about 13 days.

### Claim 27

The method of any preceding claim, wherein step (b) comprises initially seeding the processed resected tumor product in a whole culture volume of cell culture medium, adding the cell culture medium at a first time point, conditionally adding the cell culture medium at a second time point based on cell concentration, and optionally conditionally adding the cell culture medium at a third time point based on cell concentration.

### Claim 28 (depends on 27)

The method of claim 27, wherein a half culture volume (0.5×) of cell culture medium is added at the first time point.

### Claim 29 (depends on 27, 28)

The method of claim 27 or 28, wherein adding the cell culture medium at the second and third time points is determined based on CD45+ viable cell density.

### Claim 30 (depends on 29)

The method of claim 29, wherein a half culture volume (0.5×) of cell culture medium is added at the second time point if CD45+ viable cell density is greater than 0.5×106 cells/mL, and wherein no culture medium is added at the second time point if CD45+ viable cell density is less than 0.5×106 cells/mL.

### Claim 31 (depends on 30)

The method of claim 30, wherein step (b) comprises initially seeding the processed resected tumor product in a 70-mL cell culture bag, and the processed resected tumor product is transferred to a 120-mL cell culture bag at the second time point if CD45+ viable cell density is greater than 0.5×106 cells/mL.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the processed resected tumor product is kept in a 70-mL cell culture bag throughout the entire first expansion.

### Claim 33 (depends on 29, 30, 31, 32)

The method of any one of claims 29-32, wherein a whole culture volume (1×) of cell culture medium is added at the third time point if CD45+ viable cell density is greater than 0.5×106 cells/mL, and wherein a half culture volume (0.5×) of cell culture medium is added at the third time point if CD45+ viable cell density is less than 0.5×106 cells/mL.

### Claim 34 (depends on 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 27-33, wherein the method proceeds to step (c) instead of adding the cell culture medium at the third time point if there are greater than about 20×106 CD3+ cells/mL, optionally wherein the third time point is day 11.

### Claim 35 (depends on 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 27-34, wherein step (b) is about 11 to about 13 days, wherein the first time point is between about day 5 and about day 7, the second time point is between about day 7 and about day 9, and the third time point is between about day 10 and about day 12.

### Claim 36 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 27-35, wherein step (b) is about 11 to about 13 days, wherein the first time point is at about day 6, the second time point is at about day 8, and the third time point is at about day 11.

### Claim 37

The method of any preceding claim, further comprising cryopreserving all or a portion of the first population of TILs prior to step (c).

### Claim 38 (depends on 37)

The method of claim 37, further comprising washing and/or concentrating all or a portion of the first population of TILs prior to the cryopreserving.

### Claim 39

The method of any preceding claim, wherein the method comprises advancing a first subpopulation of TILs from step (b) to step (c) without cryopreserving the first subpopulation, and cryopreserving the excess TILs.

### Claim 40

The method of any preceding claim, wherein if there are greater than about 20×106 CD3+ cells at the end of step (b), the excess TILs are cryopreserved.

### Claim 41 (depends on 39, 40)

The method of claim 39 or 40, wherein step (c) is repeated with the cryopreserved excess TILs.

### Claim 42

The method of any preceding claim, further comprising washing and/or concentrating the first population of TILs.

### Claim 43

The method of any preceding claim, wherein the first population of TILs is washed prior to step (c).

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 1-42, wherein the first population of TILs is not washed prior to step (c).

### Claim 45

The method of any preceding claim, wherein the first population of TILs comprises a mixture of resident and emergent T cells.

### Claim 46

The method of any preceding claim, wherein the first population of TILs that is cultured in step (c) comprises between about 0.75×106 cells and about 20×106 cells or between about 1×106 cells and about 20×106 cells.

### Claim 47

The method of any preceding claim, wherein the CD3 agonist antibody is OKT-3.

### Claim 48

The method of any preceding claim, wherein the second cell culture medium comprises between about 300 and about 3000 IU/mL IL-2.

### Claim 49

The method of any preceding claim, wherein the second cell culture medium comprises between about 1500 and about 2500 IU/mL IL-2 or between about 1750 and about 2250 IU/mL IL-2, or wherein the second cell culture medium comprises less than 3000, less than 2500, or less than 2250 IU/mL IL-2.

### Claim 50

The method of any preceding claim, wherein the second cell culture medium comprises about 2000 IU/mL of IL-2.

### Claim 51

The method of any preceding claim, wherein the second cell culture medium does not comprise fetal bovine serum (FBS).

### Claim 52

The method of any preceding claim, wherein the second cell culture medium comprises human AB serum.

### Claim 53

The method of any preceding claim, wherein the second cell culture medium further comprises IL-7, IL-12, IL-15, IL-18, IL-21, or a combination thereof.

### Claim 54

The method of any preceding claim, wherein the APCs are obtained by apheresis.

### Claim 55

The method of any preceding claim, wherein the APCs comprise peripheral blood mononuclear cells (PBMCs), wherein the PBMCs comprise fresh or cryopreserved PBMCs.

### Claim 56

The method of any preceding claim, wherein the APCs comprise PBMCs from 2 to 10 donors, from 2-5 donors, from 3-4 donors, or from 3 donors.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 1-53, wherein the APCs are artificial APCs.

### Claim 58

The method of any preceding claim, wherein the expansion in step (c) comprises a static expansion followed by a dynamic expansion.

### Claim 59 (depends on 58)

The method of claim 58, wherein the static expansion is performed in a 3 L bag, optionally wherein the bag is a ethylene vinyl acetate (EVA) bag or a fluorinated ethylene propylene (FEP) bag.

### Claim 60 (depends on 58, 59)

The method of claim 58 or 59, wherein the static expansion is for about 5 to about 7 days, and wherein the dynamic expansion is for about 7 to about 9 days.

### Claim 61 (depends on 58, 59, 60)

The method of any one of claims 58-60, wherein the static expansion is performed in a working volume of about 1500 mL to about 2500 mL or about 1750 mL to about 2250 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 500 mL to about 750 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells.

### Claim 62 (depends on 58, 59, 60, 61)

The method of any one of claims 58-61, wherein the static expansion is performed in a working volume of about 2000 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 625 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells.

### Claim 63 (depends on 58, 59, 60, 61, 62)

The method of any one of claims 58-62, wherein the dynamic expansion is performed in a working volume of about 2400 mL to about 4000 mL or about 2800 mL to about 3600 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 500 mL to about 1500 mL or about 750 mL to about 1250 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells.

### Claim 64 (depends on 58, 59, 60, 61, 62, 63)

The method of any one of claims 58-63, wherein the dynamic expansion is performed in a working volume of about 3200 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 1000 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells.

### Claim 65 (depends on 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 58-64, wherein the dynamic expansion comprises rocking the first population of cells at a rocking angle of about 8 degrees.

### Claim 66 (depends on 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 58-65, wherein the dynamic expansion comprises perfusion steps at fourth, fifth, and sixth time points, wherein the perfusion comprises removing spent cell culture medium while simultaneously adding fresh cell culture medium in equal parts to maintain a constant culture volume.

### Claim 67 (depends on 66)

The method of claim 66, wherein the fourth time point is days 20-21, wherein the fifth time point is days 22-23, and wherein the sixth time point is days 24-30.

### Claim 68 (depends on 66, 67)

The method of claim 66 or 67, wherein the perfusion at the fourth time point is about 0.6 to about 1 L/day, the perfusion at the fifth time point is about 1.4 to about 1.8 L/day, and the perfusion at the sixth time point is about 3 to about 3.4 L/day if the first population of TILs is between about 3×106 cells and about 20×106 cells, and
wherein the perfusion at the fourth time point is about 0.2 to about 0.3 L/day, the perfusion at the fifth time point is about 0.4 to about 0.6 L/day, and the perfusion at the sixth time point is about 0.8 to about 1.2 L/day if the first population of TILs is between about 0.75×106 cells and about 3×106 cells.

### Claim 69 (depends on 66, 67, 68)

The method of any one of claims 66-68, wherein the perfusion at the fourth time point is about 0.8 L/day, the perfusion at the fifth time point is about 1.6 L/day, and the perfusion at the sixth time point is about 3.2 L/day if the first population of TILs is between about 3×106 cells and about 20×106 cells, and
wherein the perfusion at the fourth time point is about 0.25 L/day, the perfusion at the fifth time point is about 0.5 L/day, and the perfusion at the sixth time point is about 1 L/day if the first population of TILs is between about 0.75×106 cells and about 3×106 cells.

### Claim 70

The method of any preceding claim, wherein the harvesting is performed when there are at least 5.0×109 CD3+ total viable cells or at least 8.5×109 CD3+ total viable cells.

### Claim 71

The method of any preceding claim, wherein the harvesting is performed using a harvest media comprising at least 2%, at least 3%, at least 4%, or at least 5% human serum albumin (HSA) and PBS.

### Claim 72

The method of any preceding claim, wherein the harvesting is performed using a harvest media comprising about 5% human serum albumin (HSA) and PBS.

### Claim 73

The method of any preceding claim, wherein step (d) further comprises formulating the TILs with HSA and DMSO.

### Claim 74 (depends on 73)

The method of claim 73, wherein the TIL formulation in step (d) comprises no more than 8%, no more than 7%, no more than 6%, no more than 5%, no more than 4%, no more than 3%, or no more than 2.5% HSA and no more than 9%, no more than 8%, no more than 7%, no more than 6%, or no more than 5% DMSO.

### Claim 75 (depends on 73, 74)

The method of claim 73 or 74, wherein the TIL formulation in step (d) comprises about 2.5% HSA and about 5% DMSO.

### Claim 76 (depends on 73, 74, 75)

The method of any one of claims 73-75, wherein the formulating comprises adding HSA and DMSO to the second population of TILs in a closed system.

### Claim 77

The method of any preceding claim, wherein the harvested TILs are cryopreserved.

### Claim 78

The method of any preceding claim, further comprising assessing the potency of the harvested TILs.

### Claim 79 (depends on 78)

The method of claim 78, wherein assessing the potency of the harvested TILs comprises:
(i) co-culturing a subpopulation of the harvested TILs with engineered cells that activate the subpopulation of the harvested TILs via CD3 or co-culturing the subpopulation of the harvested TILs with autologous tumor cells;
(ii) detecting the presence or absence of viable CD2+ T-cells that express one or both of IFN-γ and CD107a in the activated TILs; and
(iii) determining the percent potency based on the percentage of TILs that express one or both of IFN-γ and CD107a.

### Claim 80 (depends on 79)

The method of claim 79, wherein the detecting comprises flow cytometry gated on viable CD2+ TILs to measure the frequency of expression of one or both of IFN-γ and CD107a.

### Claim 81

The method of any preceding claim, wherein the first cell culture medium comprises fetal bovine serum (FBS) and about 2000 IU/mL of IL-2,
wherein step (b) comprises initially seeding the processed resected tumor product in about 20 to about 40 mL of the cell culture medium in a 70-mL cell culture bag,
wherein step (b) comprises initially seeding the processed resected tumor product in a whole culture volume of cell culture medium, adding the cell culture medium at a first time point, conditionally adding the cell culture medium at a second time point based on cell concentration, and optionally conditionally adding the cell culture medium at a third time point based on cell concentration,
wherein a half culture volume (0.5×) of cell culture medium is added at the first time point,
wherein adding the cell culture medium at the second and third time points is determined based on CD45+ viable cell density,
wherein a half culture volume (0.5×) of cell culture medium is added at the second time point if CD45+ viable cell density is greater than 0.5×106 cells/mL, and wherein no culture medium is added at the second time point if CD45+ viable cell density is less than 0.5×106 cells/mL,
wherein a whole culture volume (1×) of cell culture medium is added at the third time point if CD45+ viable cell density is greater than 0.5×106 cells/mL, and wherein a half culture volume (0.5×) of cell culture medium is added at the third time point if CD45+ viable cell density is less than 0.5×106 cells/mL,
wherein step (b) is from about 10 to about 13 days or from about 11 to about 13 days, optionally wherein the first time point is between about day 5 and about day 7, the second time point is between about day 7 and about day 9, and the third time point is between about day 10 and about day 12, and
optionally wherein the method proceeds to step (c) instead of adding the cell culture medium at the third time point if there are greater than about 20×106 CD3+ cells/mL, optionally wherein the third time point is day 11.

### Claim 82

The method of any preceding claim, wherein the first population of TILs that is cultured in step (c) comprises between about 0.75×106 cells and about 20×106 cells or between about 1×106 cells and about 20×106 cells,
wherein the second cell culture medium comprises about 2000 IU/mL of IL-2,
wherein the second cell culture medium comprises human AB serum but does not comprise FBS,
wherein the expansion in step (c) comprises a static expansion followed by a dynamic expansion,
wherein the static expansion is performed in a 3 L bag, optionally wherein the bag is a ethylene vinyl acetate (EVA) bag or a fluorinated ethylene propylene (FEP) bag,
wherein the static expansion is for about 5 to about 7 days, and wherein the dynamic expansion is for about 7 to about 9 days,
wherein the static expansion is performed in a working volume of about 1500 mL to about 2500 mL or about 1750 mL to about 2250 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 500 mL to about 750 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the static expansion is performed in a working volume of about 2000 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 625 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the dynamic expansion is performed in a working volume of about 2400 mL to about 4000 mL or about 2800 mL to about 3600 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 500 mL to about 1500 mL or about 750 mL to about 1250 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the dynamic expansion is performed in a working volume of about 3200 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 1000 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the dynamic expansion comprises rocking the first population of cells at a rocking angle of about 8 degrees,
wherein the dynamic expansion comprises perfusion steps at fourth, fifth, and sixth time points, wherein the perfusion comprises removing spent cell culture medium while simultaneously adding fresh cell culture medium in equal parts to maintain a constant culture volume,
wherein the fourth time point is days 20-21, wherein the fifth time point is days 22-23, and wherein the sixth time point is days 24-30,
wherein the perfusion at the fourth time point is about 0.6 to about 1 L/day, the perfusion at the fifth time point is about 1.4 to about 1.8 L/day, and the perfusion at the sixth time point is about 3 to about 3.4 L/day if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the perfusion at the fourth time point is about 0.2 to about 0.3 L/day, the perfusion at the fifth time point is about 0.4 to about 0.6 L/day, and the perfusion at the sixth time point is about 0.8 to about 1.2 L/day if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the perfusion at the fourth time point is about 0.8 L/day, the perfusion at the fifth time point is about 1.6 L/day, and the perfusion at the sixth time point is about 3.2 L/day if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the perfusion at the fourth time point is about 0.25 L/day, the perfusion at the fifth time point is about 0.5 L/day, and the perfusion at the sixth time point is about 1 L/day if the first population of TILs is between about 0.75×106 cells and about 3×106 cells.

### Claim 83

The method of any preceding claim, wherein the harvesting is performed using a harvest media comprising about 5% human serum albumin (HSA) and PBS,
wherein the TIL formulation in step (d) comprises about 2.5% HSA and about 5% DMSO, and
wherein the formulating comprises adding HSA and DMSO to the second population of TILs in a closed system.

### Claim 84

The method of any preceding claim, wherein the first cell culture medium comprises fetal bovine serum (FBS) and about 2000 IU/mL of IL-2,
wherein step (b) comprises initially seeding the processed resected tumor product in about 20 to about 40 mL of the cell culture medium in a 70-mL cell culture bag,
wherein step (b) comprises initially seeding the processed resected tumor product in a whole culture volume of cell culture medium, adding the cell culture medium at a first time point, conditionally adding the cell culture medium at a second time point based on cell concentration, and optionally conditionally adding the cell culture medium at a third time point based on cell concentration,
wherein a half culture volume (0.5×) of cell culture medium is added at the first time point,
wherein adding the cell culture medium at the second and third time points is determined based on CD45+ viable cell density,
wherein a half culture volume (0.5×) of cell culture medium is added at the second time point if CD45+ viable cell density is greater than 0.5×106 cells/mL, and wherein no culture medium is added at the second time point if CD45+ viable cell density is less than 0.5×106 cells/mL,
wherein a whole culture volume (1×) of cell culture medium is added at the third time point if CD45+ viable cell density is greater than 0.5×106 cells/mL, and wherein a half culture volume (0.5×) of cell culture medium is added at the third time point if CD45+ viable cell density is less than 0.5×106 cells/mL,
wherein step (b) is from about 10 to about 13 days or from about 11 to about 13 days, optionally wherein the first time point is between about day 5 and about day 7, the second time point is between about day 7 and about day 9, and the third time point is between about day 10 and about day 12, and
optionally wherein the method proceeds to step (c) instead of adding the cell culture medium at the third time point if there are greater than about 20×106 CD3+ cells/mL, optionally wherein the third time point is day 11,
wherein the first population of TILs that is cultured in step (c) comprises between about 0.75×106 cells and about 20×106 cells or between about 1×106 cells and about 20×106 cells,
wherein the second cell culture medium comprises about 2000 IU/mL of IL-2,
wherein the second cell culture medium comprises human AB serum but does not comprise FBS,
wherein the expansion in step (c) comprises a static expansion followed by a dynamic expansion,
wherein the static expansion is performed in a 3 L bag, optionally wherein the bag is a ethylene vinyl acetate (EVA) bag or a fluorinated ethylene propylene (FEP) bag,
wherein the static expansion is for about 5 to about 7 days, and wherein the dynamic expansion is for about 7 to about 9 days,
wherein the static expansion is performed in a working volume of about 1500 mL to about 2500 mL or about 1750 mL to about 2250 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 500 mL to about 750 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the static expansion is performed in a working volume of about 2000 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 625 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the dynamic expansion is performed in a working volume of about 2400 mL to about 4000 mL or about 2800 mL to about 3600 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 500 mL to about 1500 mL or about 750 mL to about 1250 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the dynamic expansion is performed in a working volume of about 3200 mL if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the static expansion is performed in a working volume of about 1000 mL if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the dynamic expansion comprises rocking the first population of cells at a rocking angle of about 8 degrees,
wherein the dynamic expansion comprises perfusion steps at fourth, fifth, and sixth time points, wherein the perfusion comprises removing spent cell culture medium while simultaneously adding fresh cell culture medium in equal parts to maintain a constant culture volume,
wherein the fourth time point is days 20-21, wherein the fifth time point is days 22-23, and wherein the sixth time point is days 24-30,
wherein the perfusion at the fourth time point is about 0.6 to about 1 L/day, the perfusion at the fifth time point is about 1.4 to about 1.8 L/day, and the perfusion at the sixth time point is about 3 to about 3.4 L/day if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the perfusion at the fourth time point is about 0.2 to about 0.3 L/day, the perfusion at the fifth time point is about 0.4 to about 0.6 L/day, and the perfusion at the sixth time point is about 0.8 to about 1.2 L/day if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the perfusion at the fourth time point is about 0.8 L/day, the perfusion at the fifth time point is about 1.6 L/day, and the perfusion at the sixth time point is about 3.2 L/day if the first population of TILs is between about 3×106 cells and about 20×106 cells, and wherein the perfusion at the fourth time point is about 0.25 L/day, the perfusion at the fifth time point is about 0.5 L/day, and the perfusion at the sixth time point is about 1 L/day if the first population of TILs is between about 0.75×106 cells and about 3×106 cells,
wherein the harvesting is performed using a harvest media comprising about 5% human serum albumin (HSA) and PBS,
wherein the TIL formulation in step (d) comprises about 2.5% HSA and about 5% DMSO, and
wherein the formulating comprises adding HSA and DMSO to the second population of TILs in a closed system.

### Claim 85

A therapeutic population of TILs obtained by method of any preceding claim.

### Claim 86 (depends on 85)

The therapeutic population of TILs of claim 85, comprising at least two therapeutic TIL populations formulated for separate administration.

### Claim 87 (depends on 85, 86)

The therapeutic population of TILs of claim 85 or 86, wherein the TILs are cryopreserved.

### Claim 88 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

A method of treating a subject having a cancer, comprising administering a therapeutic population of TILs obtained by the method of any one of claims 1-84 to the subject.

### Claim 89 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

A method of treating a subject having a cancer, comprising administering first and second therapeutic populations of TILs obtained by the method of any one of claims 1-84 to the subject.

### Claim 90 (depends on 88, 89)

The method of claim 88 or 89, wherein the cancer is melanoma, cervical cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), or cutaneous squamous cell carcinoma (cSCC).

### Claim 91 (depends on 88, 89, 90)

The method of any one of claims 88-90, wherein the cancer is melanoma.

### Claim 92 (depends on 88, 89, 90)

The method of any one of claims 88-90, wherein the cancer is cervical cancer, non-small cell lung cancer (NSCLC), or head and neck squamous cell carcinoma (HNSCC).
